Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden

Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer

(2013) J Kumar et al.   BRITISH JOURNAL OF CANCER

Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets

(2013) Nuzhat Ahmed et al.   MOLECULAR ASPECTS OF MEDICINE

Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden

(2013) Khalid Abubaker et al.   Molecular Cancer

STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers

(2012) XIAOCHUN WANG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Cancerous ovarian stem cells: Obscure targets for therapy but relevant to chemoresistance

(2012) Nuzhat Ahmed et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies

(2012) Pasquale Sansone et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivo

(2012) R B Luwor et al.   ONCOGENE

Isolation and Characterization of Tumor Cells from the Ascites of Ovarian Cancer Patients: Molecular Phenotype of Chemoresistant Ovarian Tumors

(2012) Ardian Latifi et al.   PLoS One

Overcoming Challenges of Ovarian Cancer Stem Cells: Novel Therapeutic Approaches

(2012) Cristóbal Aguilar-Gallardo et al.   Stem Cell Reviews and Reports

Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects

(2012) Beverly Barton et al.   OncoTargets and Therapy

A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment

(2011) H. Kulbe et al.   CANCER RESEARCH

Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance

(2011) Ayesha B. Alvero et al.   CELL CYCLE

Absolute requirement for STAT3 function in small-intestine crypt stem cell survival

(2011) J R Matthews et al.   CELL DEATH AND DIFFERENTIATION

Stat3: Linking inflammation to (gastrointestinal) tumourigenesis

(2011) Matthias Ernst et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer

(2011) A. D. Steg et al.   CLINICAL CANCER RESEARCH

The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells

(2011) K A Monaghan et al.   LEUKEMIA

Notch post-translationally regulates β-catenin protein in stem and progenitor cells

(2011) Chulan Kwon et al.   NATURE CELL BIOLOGY

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

(2010) J. W. Tyner et al.   BLOOD

Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells

(2010) Yue Wang et al.   CANCER LETTERS

Epithelial Mesenchymal Transition and Cancer Stem Cell-Like Phenotypes Facilitate Chemoresistance in Recurrent Ovarian Cancer

(2010) N. Ahmed et al.   CURRENT CANCER DRUG TARGETS

Back to the future: Targeting molecular changes for platinum resistance reversal

(2010) Hani Gabra   GYNECOLOGIC ONCOLOGY

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

(2009) C. J. Creighton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

STAT3 Is Required for Proliferation and Maintenance of Multipotency in Glioblastoma Stem Cells

(2009) Maureen M. Sherry et al.   STEM CELLS

Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial–mesenchymal transition in ovarian carcinomas

(2008) M Colomiere et al.   BRITISH JOURNAL OF CANCER

Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents

(2008) Yuval Shaked et al.   CANCER CELL

STAT 3 as a Target for Cancer Drug Discovery

(2008) Luca Costantino et al.   CURRENT MEDICINAL CHEMISTRY

Hyaluronan-CD44 Interaction Activates Stem Cell Marker Nanog, Stat-3-mediated MDR1 Gene Expression, and Ankyrin-regulated Multidrug Efflux in Breast and Ovarian Tumor Cells

(2008) Lilly Y. W. Bourguignon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The function of Stat3 in tumor cells and their microenvironment

(2008) Bernd Groner et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Wnt signaling in ovarian tumorigenesis

(2007) T.A. GATCLIFFE et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER